Diabeloop receives FDA 510(k) clearance for DBLG2, an Automated Insulin Delivery algorithm in an App: a strategic ...

The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics’ ...

MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE ...

Broad availability of the twiist and Eversense 365 integrated product is expected by March 2026, as per the company.

TORONTO — Clinical trials have shown that many automated insulin delivery (AID) systems are safe and effective for nonpregnant patients with type 1 diabetes (T1D). They are associated with improved ...

Omnipod 5 is the first AID system cleared for type 1 and type 2 diabetes management. Insulet’s Omnipod ® 5 Automated Insulin Delivery (AID) System has been cleared by the Food and Drug Administration ...

After the initiation of an AID system, glycemic control improved and the effect persisted throughout the study period. (HealthDay News) — Initiation of an automated insulin delivery (AID) system ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people with insulin-treated type 2 diabetes (T2D), a new randomized trial showed.

MANCHESTER, N.H., May 22, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies today announced a commercial development agreement for ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point greater drop in HbA1c than controls. The AID group also spent 3.4 more hours per ...